Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Off-Label Debate Between FDA, Industry To Formally Begin After Election

Aug 31 2016

• By Michael Cipriano

FDA entrance sign 2016

Related Content

Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement

Mar 14 2016

US FDA Sets Goal For Biosimilar, Drug Promotion Guidances

Jan 26 2016

Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes

Jul 27 2016

Off-Label Communications: BIO Lays Ethical Foundation For Change

Aug 09 2016

Related Companies

Amarin Corp plc

Additional Topics

United States Legal Issues Regulation BioPharmaceutical

More from Legal & IP

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window